Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
  • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

• the present invention relates to 5-HT 6 receptor antagonists for the treatment of Alzheimer's disease with comorbid apathy comprising administering an effective dose of a 5-HT 6 receptor antagonist to improve or augment the effect of an acetylcholinesterase inhibitor.
• Dementia is a clinical syndrome characterized by deficits in multiple areas of cognition that cannot be explained by normal aging, a noticeable decline in function, and an absence of delirium.
• neuropsychiatric symptoms are often present already at first diagnosis and then increase in numbers and intensity over time as the disease progresses.
• the neuropsychiatric symptoms in Alzheimer's disease (AD) patients are diverse and range from apathy to agitation.
• selective 5-HT 6 receptor antagonists to treat cognitive dysfunction has been suggested and is based on several lines of reasoning. For example, selective 5-HT 6 receptor antagonists have been shown to modulate cholinergic and glutamatergic neuronal function. The activity of selective 5-HT 6 receptor antagonists has been demonstrated in animal models of cognitive function. Since the disclosure of the first selective 5-HT 6 receptor antagonists, there have been several reports on the activity of these selective compounds in in-vivo models of cognitive function.
• N-(2-(6-fluoro- i/-/-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine INN-name idalopirdine, is a potent and selective 5-HT 6 receptor antagonist which is currently in clinical development.
• N-(2-(6-fluoro- i/-/-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine has also been disclosed as Lu AE58054.
• N-(2-(6-fluoro- i/-/-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine is for the first time disclosed in WO 02/078693 and a dose range for A-(2-(6-fluoro- iH-indol-3-yl)-ethyl)-3- (2,2,3,3-tetrafluoropropoxy)-benzylamine is disclosed in WO 2014/037532.
• LADDER study assessed the effect on cognitive performance of idalopirdine in donepezil- treated patients with moderate AD.
• Avineuro Pharmaceuticals is developing an oral small-molecule 5-HT 6 receptor antagonist, AVN-21 1 (CD-008-0173), for the potential treatment of the cognitive symptoms as well as for Alzheimer's disease.
• AVN-21 1 is a 3-sulfonyl-pyrazolo[1 ,5-a]pyrimidine derivative and is disclosed in WO 2009/093206 as 3-Benzenesulfonyl-5,7-dimethyl-2-methylsulfanyl-pyrazolo[1 ,5- a]pyrimidine.
• RVT-101 is an 8-piperazin-1 -yl quinoline derivative and is disclosed in WO 2009/093206 as 3-phenylsulfonyl-8-piperazin-1 -yl-quinoline.
• the present provides a treatment of Alzheimer's disease with a 5-HT 6 receptor antagonist as an adjunctive therapy to acetylcholinesterase inhibitors in patients where apathy is comorbid.
• Apathy is characterized by the loss of initiation and motivation to participate in activities, social withdrawal, and emotional indifference. Patients with apathy are at increased risk to progressively suffer from decreased daily function and specific cognitive deficits such as executive cognitive dysfunction. Therefore such patients tend to more early rely on families to pro- vide more care than other patients with Alzheimer's disease, which results in increased stress for families.
• apathy is a phenotypical marker for a subgroup of Alzheimer's disease patients with enhanced treatment response to the 5-HT 6 receptor antagonist idalopirdine in combination with the acetylcholinesterase inhibi- tor donepezil ((f?S)-2-[(1 -Benzyl-4-piperidyl)methyl]- 5,6-dimethoxy-2,3-dihydroinden-1 -one).
• idalopirdine is a 5-HT 6 receptor antagonist with high specificity and virtually no binding to other pharmacological receptors it is believed that other 5-HT 6 receptor antagonists, such as AVN-21 1 and RVT-101 , also will give rise to an enhanced treatment response in Alzheimer's disease patients where apathy is comorbid.
• 5-HT 6 receptor antagonists such as AVN-21 1 and RVT-101
• the first embodiment is denoted E1
• the second embodiment is denoted E2 and so forth.
• E1 A 5-HT 6 receptor antagonist or a pharmaceutically acceptable salt thereof for use in treating Alzheimer's disease where apathy is comorbid with Alzheimer's disease by improving or augmenting the effect of an acetylcholinesterase inhibitor.
• the 5-HT 6 receptor antagonist is selected from the group consisting of idalopirdine, AVN-21 1 and RVT-101 or pharmaceutically acceptable salts of said 5-HT 6 receptor antagonists.
• the 5-HT 6 receptor antagonist is idalopirdine or a pharmaceutically acceptable salt thereof.
• the 5-HT 6 receptor antagonist is the hydrochloride salt of idalopirdine.
• the 5-HT 6 receptor antagonist is AVN-21 1 or a pharma- ceutically acceptable salt thereof.
• E6 In an embodiment of E1 or E2 the 5-HT 6 receptor antagonist is RVT-101 or a pharmaceutically acceptable salt thereof.
• the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or pharmaceutically acceptable salts of said acetylcholinesterase inhibitors.
• E8 In an embodiment of E1 or E7 the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.
• E9 In an embodiment of E1 or E8 the acetylcholinesterase inhibitor is the hydrochloride salt of donepezil.
• E10 In an embodiment of E1 or E7 the acetylcholinesterase inhibitor is rivastigmine or a pharmaceutically acceptable salt thereof.
• E1 1 In an embodiment of E1 or E10 the acetylcholinesterase inhibitor is the hydrochloride salt or the tartrate salt of rivastigmine.
• E12 In an embodiment of E1 or E7 the acetylcholinesterase inhibitor is galantamine or a pharmaceutically acceptable salt thereof. E13 In an embodiment of E1 or E12 the acetylcholinesterase inhibitor is the hydrobromide salt of galantamine.
• E14 In an embodiment of E1 , E3 or E8 the 5-HT 6 receptor antagonist is idalopirdine and the acetylcholinesterase inhibitor is donepezil.
• the 5-HT 6 receptor antagonist is the hydrochloride salt of idalopirdine and the acetylcholinesterase inhibitor is the hydrochloride salt of donepezil.
• E16 In an embodiment of E1 , E14 or E15 the dosage range of idalopirdine is from 10
• E17 In an embodiment of E1 , E3, E4, E14 or E15 the dosage range of idalopirdine is from 30 mg/day to 60 mg/day.
• E18 In an embodiment of E17 the dosage of idalopirdine is 30 mg/day.
• E19 In an embodiment of E17 the dosage of idalopirdine is 60 mg/day.
• E20 In an embodiment of E1 , E8, E9, E14 or E15 the dosage range of donepezil is from 2 mg/day to 25 mg/day, preferably from 5 mg/day to 23 mg/day.
• E21 A pharmaceutical composition comprising a 5-HT 6 receptor antagonist selected from the group consisting of idalopirdine, RVT-101 and AVN-21 1 , or pharmaceutically acceptable salts of said 5-HT 6 receptor antagonists, and an acetylcholinesterase inhibitor selected from the group consisting of donepezil, rivastigmine and galantamine, or pharmaceutically acceptable salts thereof, for the treatment of Alzheimer's disease where apathy is comorbid with Alzheimer's disease.
• a 5-HT 6 receptor antagonist selected from the group consisting of idalopirdine, RVT-101 and AVN-21 1
• an acetylcholinesterase inhibitor selected from the group consisting of donepezil, rivastigmine and galantamine, or pharmaceutically acceptable salts thereof
• a 5-HT 6 receptor antagonist selected from the group consisting of idalopirdine, RVT-101 and AVN-21 1 , or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of Alzheimer's disease where apathy is comor- bid with Alzheimer's disease.
• a 5-HT 6 receptor antagonist selected from the group consisting of idalopirdine, RVT-101 and AVN-21 1 , or pharmaceutically acceptable salts 5-HT 6 receptor antagonist, and an acetylcholinesterase inhibitor selected from the group consisting of donepezil, rivastigmine and galantamine, or pharmaceutically acceptable salts of ace- tylcholinesterase inhibitors, for the manufacture of a medicament for the treatment of
• Alzheimer's disease where apathy is comorbid with Alzheimer's disease.
• the Alzheimer's disease is at a mild to moderate stage.
• Alzheimer's disease is at a moderate to severe stage.
• the term "5-HT 6 receptor antagonist” as well as any specific 5- HT 6 receptor antagonist, such as idalopirdine, AVN-21 1 or RVT-101 is intended to include, unless otherwise specified, any form of the compound, such as the free base and pharmaceutically acceptable salts.
• the free base and pharmaceutically acceptable salts include an- hydrous forms and solvated forms such as hydrates.
• the anhydrous forms include amorphous and crystalline forms, and the solvates include crystalline forms.
• the term “5-HT 6 receptor antagonist” includes the human 5-HT 6 receptor antagonist (which also may be denoted "h5-HT 6 receptor antagonist").
• acetylcholinesterase inhibitor (abbreviated “AChEI) as well as any spe- cific acetylcholinesterase inhibitor, such as “donepezil”, is intended to include any form of the compound, such as the free base and pharmaceutically acceptable salts etc.
• acetylcholinesterase inhibitor (AChEI) is known to those skilled in art and includes compounds selected from the group consisting of donepezil ((flS)-2-[(1 -Benzyl-4- piperidyl)methyl]- 5,6-dimethoxy-2,3-dihydroinden-1 -one), rivastigmine ((S)-3-[1 -(dimethyl- amino)ethyl]phenyl N-ethyl-N-methylcarbamate) , galantamine ((4aS,6f?,8aS)-5,6,9,10,1 1 ,12- Hexahydro-3-methoxy-1 1 -methyl-4a/-/-[1 ]benzofuro[3a,3,2-e/
• donepezil ((flS)-2-[(1 -Benz
• the FDA approved dosages of the acetylcholinesterase inhibitor are encompassed by the instant invention.
• the dosages of donepezil are shown to be effective in controlled clinical trials of the treatment of mild to moderate Alz- heimer's disease are 5 mg or 10 mg administered orally once per day.
• a 23 mg orally once daily dose of donepezil is also approved for treating moderate to severe AD.
• a 5-HT 6 receptor antagonist such as idalopirdine, AVN-21 1 or RVT-101 or any other 5-HT 6 receptor antagonist
• an AChEI such as donepezil, rivastigmine, tacrine or galantamine
• a 5-HT 6 receptor antagonist when used in combination with an AChEI, this indicates that said two compounds are ad- ministered separately in suitable individual pharmaceutical compositions.
• These individual compositions may be administered simultaneously e.g. with regular intervals once daily either morning or evening, or they may be administered independently e.g. one compound with regular intervals once daily in the morning and the other compound with regular intervals once daily in the evening.
• comorbidity refers to one more than one disorders or diseases (such as apathy) that exist alongside a primary diagnosis (such as Alzheimer's disease) where the primary diagnosis is the reason a patient gets referred and/or treated.
• disorders or diseases such as apathy
• a primary diagnosis such as Alzheimer's disease
• Apathy is in the context of the present invention defined as a score of 1 or higher, such as a score of 2, or 3, or 4, or 6, or 8, or 12 obtained through application of the NPI instrument.
• the NPI is a 12-item validated structured interview with a caregiver, designed to assess behavioural disturbances in patients with dementia, and includes ten behavioural areas, including apathy, and two neurovegetative areas. The NPI is further described in Cummings JL et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994 ; 44 : 2308- 14.
• a “therapeutically effective dose" of 5-HT 6 receptor antagonist is an amount sufficient to provide an observable therapeutic benefit compared to baseline clinically observable signs and symptoms of Alzheimer's disease as measured by ADAS-cog (Rosen WG et al. A new scale for Alzheimer's disease. Am J Psychiatry 1984; 141 : 1356-64), and Alzheimer's disease- related dementia treated in connection with the combination therapy.
• dose is used herein to mean administration of 5-HT 6 receptor antagonist or acetylcholinesterase inhibitor in one dosage form to the patient being treated.
• the dose is a single oral formulation.
• the dose is formulated as a tablet, a capsule, a pill, or a patch administered to the patient.
• a "unit dosage form” refers to a formulation unit of a pharmaceutical composition e.g. a tablet or a capsule.
• an effective daily dose means the total amount of 5-HT 6 receptor antagonist or AChEI administered to a patient in need of therapy in a continuous, twenty-four (24) hour period.
• an effective daily dose of 90 mg shall mean and include administering a single dose of 90 mg in a twenty four hour period, administering two doses of 45 mg each within a twenty four hour period, and administering three doses of 30 mg each in a twenty four hour period, and so on.
• administering 5-HT 6 receptor antagonist in such a manner i.e. more than once in a twenty four hour period, such administrations can be spread evenly through the twenty four hour period or even be administered simultaneously or nearly so.
• dose range refers to an upper and a lower limit of an acceptable variation of the amount of agent specified. Typically, a dose of the agent in any amount within the specified range can be administered to patients undergoing treatment.
• treat is used herein to mean to relieve, reduce or alleviate at least one symptom of a disease in a subject.
• the term “treat” may mean to re- lieve or alleviate cognitive impairment (such as impairment of memory and/or orientation) or impairment of global functioning (overall functioning, including activities of daily living) and/or slow down or reverse the progressive deterioration in global or cognitive impairment.
• the present invention also comprises salts of the 5-HT 6 receptor antagonists, typically, phar- maceutically acceptable salts.
• Such salts include pharmaceutically acceptable acid addition salts.
• Acid addition salts include salts of inorganic acids as well as organic acids.
• Suitable inorganic acids include hydrochloric, hydrobromic, hy- droiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like.
• suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulf
• the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
• pharmaceutically acceptable solvents such as water, ethanol and the like.
• the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
• 5-HT 6 receptor antagonist is in the form of a hydrochloric salt of idalopirdine.
• the present invention further provides a pharmaceutical composition comprising a therapeu- tically effective amount of a 5-HT 6 receptor antagonist and a pharmaceutically acceptable carrier or diluent.
• the present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of one of the 5-HT 6 receptor antagonist and a pharmaceutically acceptable carrier or diluent.
• the 5-HT 6 receptor antagonist may be administered alone or in combination with pharmaceu- tically acceptable carriers, diluents or excipients, in either single or multiple doses.
• the pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 21 st Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 2005.
• compositions may be specifically formulated for administration by any suitable route such as oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal and parenteral (including subcutaneous, intramuscular and intravenous) routes. It will be appreciated that the route will depend on the general condition and age of the sub- ject to be treated, the nature of the condition to be treated and the active ingredient.
• compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, the compositions may be prepared with coatings such as enteric coatings or they may be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art.
• Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
• compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use.
• Other suitable administration forms include, but are not limited to, suppositories, sprays, ointments, creams, gels, inhalants, dermal patches and implants.
• Typical oral dosages range from about 0.001 to about 100 mg/kg body weight per day. Typical oral dosages also range from about 0.01 to about 50 mg/kg body weight per day. Typical oral dosages further range from about 0.05 to about 10 mg/kg body weight per day.
• Oral dosages are usually administered in one or more dosages, typically, one to three dosages per day.
• the exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.
• a typical unit dosage form for oral administration may contain from about 0.01 to about 1000 mg, from about 0.05 to about 500 mg, or from about 0.5 mg to about 200 mg.
• the 5-HT 6 receptor antagonists of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
• One example is an acid addition salt of a 5- HT 6 receptor antagonist which has the same utility as of a free base.
• a 5-HT 6 receptor antagonist contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of the 5-HT 6 receptor antagonist with a pharmaceutically acceptable acid.
• suitable organic and inorganic acids are described above.
• solutions of the 5-HT 6 receptor antagonist in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed.
• aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
• the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
• the 5-HT 6 receptor antagonist may be readily incorporated into known sterile aqueous media using standard techniques known to those skilled in the art.
• Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
• solid carriers include lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose.
• liquid carriers include, but are not limited to, syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water.
• the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
• sustained release material such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
• Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and optionally a suitable excipient.
• the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
• the preparation may be tableted, placed in a hard gelatin capsule in powder or pellet form or it may be in the form of a troche or lozenge.
• the amount of solid carrier will vary widely but will range from about 25 mg to about 1 g per dosage unit.
• the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
• compositions of the invention may be prepared by conventional methods in the art.
• tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tablet- ing machine prepare tablets.
• adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatin, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colorings, flavorings, preservatives etc. may be used provided that they are compatible with the active ingredients.
• the 5-HT6 receptor antagonist is generally utilized as the free substance or as a pharmaceutically acceptable salt thereof. Examples of suitable organic and inorganic acids are described above.
• the dosing regime for the 5-HT 6 antagonist will depend on the actual pharmacokinetic profile of the antagonist, but generally the dose range will be 5-200 mg/day dosed once or twice daily.
• the preferred dose range is 10-90 mg/day dosed once or twice daily, pref- erably once daily.
• the preferred dose range for idalopirdine is 30-60 mg/day dosed once daily.
• the dosing regime for the AChEI will depend on the actual pharmacokinetic profile of the inhibitor, but generally the dose range will be 5-200 mg/day dosed once or twice daily.
• Galan- tamine is typically dosed from 8 mg/day to 24 mg/day
• rivastigmine is typically dosed from 3 mg/day to 12 mg/day
• donepezil is typically dosed from 5 mg/day to 23 mg/day.
• the 5-HT 6 antagonist may be administered simultaneously with an AChEI or the 5-HT 6 antagonist and the AChEI may be administered independently of each other.
• the two compounds may be contained in the same unit dosage form (e.g. a single tablet comprising both the 5-HT 6 receptor antagonist and an AChEI) or in separate unit dosage forms (e.g. two tablets comprising the 5-HT 6 receptor antagonist and an AChEI respectively).
• the dose is calculated on the basis of the free base of the active pharmaceutical ingredient.
• Headings and sub-headings are used herein for convenience only, and should not be con- strued as limiting the invention in any way.
• the LADDER study that was conducted to assess the effect on cognitive performance of idalopirdine in donepezil-treated patients with moderate Alzheimer's disease.
• LADDER a 5-HT 6 receptor antagonist
• MMSE mini-mental state examination
• the cognitive subscale of the 70-point, 1 1 -item Alzheimer's Disease Assessment Scale was rated at baseline and at weeks 4, 12, and 24.
• the ADAS-Cog scale is de- scribed in Rosen WG et al. A new scale for Alzheimer's disease. Am J Psychiatry 1984; 141 : 1356-64.
• the change from baseline in the ADAS-cog at week 24 was the primary endpoint and the study showed that improvement in cognitive function was significantly better with idalopirdine than with placebo.
• Example 3 Treatment effect of idalopirdine on cognition in patients suffering from Alzheimer's disease where apathy is comorbid
• the post-hoc analysis focused on patients enrolled in the study with an apathy score of 1 or higher as measured by neuropsychiatric inventory (NPI) secondary efficacy endpoint. About 44% of the enrolled patients had an apathy score of 1 or higher at baseline:
• apathy was considered present if the apathy score as measured by Neuropsychiatric Inventory (NPI) was 1 or higher.
• NPI Neuropsychiatric Inventory
• the statistical analysis predicted a significant interaction at a 5% significance level between apathy score and treatment effect of idalopirdine on cognition as measured by the ADAS-Cog score (a negative score means less decline in cognitive skills and is thus desirable):
• Table 4 Effect on cognition at week 24 in patients with and without apathy
• Example 4 Treatment effect of idalopirdine on Activities of Daily Living (ADL) in patients suffering from Alzheimer's disease where apathy is comorbid
• Example 3 The same patient population as in Example 3 was analysed in a post-hoc analysis.
• apathy was considered present if the apathy score as measured by Neuropsychiatric Inventory (NPI) was 1 or higher.
• NPI Neuropsychiatric Inventory
• the statistical analysis predicted a significant interaction at a 5% significance level between apathy score and treatment effect of idalopirdine on Activities of Daily Living as measured by the ADCS-ADL score (Galasko et al; An inventory to assess activities of daily living for clinical trials in Alzheimer's Disease. Alzheimer Dis Assoc Disord. 1997;1 1 (Suppl 2):22-32) (a positive score means an improvement):
• 5-HT binding affinity was determined as described in Arnt J, et al. Lu AE58054, a 5-HT 6 receptor antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.
• ADAS-cog and apathy evaluated by NPI Relevant psychiatric tests (ADAS-cog and apathy evaluated by NPI) have been referenced in the description above and are hereby incorporated in full.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Emergency Medicine (AREA)
• Biomedical Technology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Psychiatry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Hospice & Palliative Care (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=58707519

Family Applications (1)

Country Status (7)

Cited By (2)

Families Citing this family (2)

Citations (5)

Family Cites Families (6)

• 2017
  • 2017-05-05 US US15/587,935 patent/US10864191B2/en active Active
  • 2017-05-09 WO PCT/EP2017/060979 patent/WO2017194496A1/en not_active Ceased
  • 2017-05-09 ES ES17723326T patent/ES2826386T3/es active Active
  • 2017-05-09 EP EP17723326.9A patent/EP3454848B1/en active Active
  • 2017-05-09 BR BR112018000568A patent/BR112018000568A2/pt not_active Application Discontinuation
  • 2017-05-09 JP JP2018559275A patent/JP6961622B2/ja active Active
  • 2017-05-09 CN CN201780028711.1A patent/CN109069466B/zh active Active
• 2021
  • 2021-10-13 JP JP2021168436A patent/JP7217789B2/ja active Active

Patent Citations (5)

Non-Patent Citations (12)

Also Published As

Similar Documents

Legal Events